Erythropoietin Therapy in Chronic Kidney Disease

Introduction to Erythropoietin Therapy

The National Kidney Foundation recommends initiating erythropoiesis-stimulating agents (ESAs) when hemoglobin falls below 10 g/dL after correcting iron deficiency and other reversible causes of anemia, targeting a hemoglobin level of 10-12 g/dL to reduce transfusion requirements while avoiding cardiovascular risks 1, 2

The American Journal of Kidney Diseases suggests correcting iron stores first by verifying transferrin saturation >20% and serum ferritin >100 ng/mL before starting ESA therapy 1, 2, 4
The American Journal of Kidney Diseases recommends ruling out reversible causes of anemia, such as B12/folate deficiency, bleeding, severe hyperparathyroidism, hypothyroidism, aluminum toxicity, and inflammatory conditions, before initiating ESA therapy 4, 5
The Kidney International Supplements guidelines advise assessing baseline blood pressure, as ESAs increase hypertension risk and require monitoring 1, 2

The Kidney International Supplements guidelines recommend starting ESA therapy when hemoglobin is sustained below 10 g/dL after correcting iron deficiency and other reversible causes of anemia, with a target hemoglobin range of 10-12 g/dL 1, 2

The Kidney International Supplements guidelines suggest a target hemoglobin of 11 g/dL, with an acceptable range of 10-12 g/dL, based on Grade A evidence for hemodialysis and non-dialysis CKD patients 1, 2

The American Journal of Kidney Diseases recommends an epoetin alfa dose of 50 Units/kg three times weekly intravenously, or 120-180 Units/kg/week in divided doses, for dialysis patients 6
The American Journal of Kidney Diseases suggests that subcutaneous administration of epoetin alfa requires a 50% lower dose than intravenous administration, if tolerated 6

The American Journal of Kidney Diseases recommends monitoring hemoglobin every 2-4 weeks initially after starting therapy or changing doses, and adjusting the dose accordingly 6, 3
The American Journal of Kidney Diseases suggests increasing the dose by 25-50% if hemoglobin increases <1 g/dL after 4 weeks, and reducing the dose by 25% or temporarily withholding therapy if hemoglobin increases >3 g/dL per month or exceeds 11 g/dL 6, 3

The American Journal of Kidney Diseases recommends using ESAs in renal transplant recipients, with careful monitoring of graft function and blood pressure 7, 8
The American Journal of Kidney Diseases suggests that iron deficiency is common in transplant recipients, occurring in 20-41% of patients, and requires supplementation 8

The Kidney International Supplements guidelines advise avoiding the error of starting ESAs without correcting iron deficiency, as this is the most common cause of poor response 1, 2, 4
The American Journal of Kidney Diseases recommends avoiding rapid correction of anemia, as increases >3 g/dL per month raise cardiovascular risk 6, 3
The Kidney International Supplements guidelines suggest ignoring blood pressure monitoring, as ESAs increase hypertension; monitor and treat aggressively 1, 2

The Praxis Medical Insights guidelines recommend stopping ESA therapy if pure red cell aplasia develops, severe uncontrolled hypertension occurs, hemoglobin consistently exceeds target range despite dose reductions, or serious adverse events potentially related to ESA therapy occur 3